131 results
6-K
EX-99.3
SNY
Sanofi
22 Mar 11
Ratio of Earnings to Fixed Charges
12:00am
€1,983 million. Had Merial not been classified as held-for-exchange in 2010 for accounting purposes, it is estimated that Merial would have generated … of the 2010 Form 20-F). Had Merial not been classified as held-for-exchange in 2009 and in 2010 for accounting purposes, it is estimated that net income would
11-K
SNY
Sanofi
28 Jun 12
Annual report of employee stock purchases
12:00am
at their unpaid principal balance plus any accrued by unpaid interest and classified as notes receivable from participants. Previously, loans were … measured at fair value and classified as investments. ASU 2010-25 was effective for fiscal years ending after December 15, 2010 and was required
11-K
SNY
Sanofi
26 Jun 15
Annual report of employee stock purchases
12:00am
, which are based on quoted market prices. They are classified within Level 1 of the valuation hierarchy.
Guaranteed Investment Contracts — Valued … -worthiness of the issuer. The traditional GICs are classified within Level 3 of the valuation hierarchy.
Synthetic Guaranteed Investment Contracts
11-K
SNY
Sanofi
26 Jun 15
Annual report of employee stock purchases
12:00am
) of shares held by the Master Trust at year end, which are based on quoted market prices. They are classified within Level 1 of the valuation … with comparable durations considering the credit-worthiness of the issuer. The traditional GICs are classified within Level 3 of the valuation hierarchy
11-K
SNY
Sanofi
25 Jun 14
Annual report of employee stock purchases
12:00am
asset value (NAV) of shares held by the Master Trust at year end, which are based on quoted market prices. They are classified within Level 1 … instrument with comparable durations considering the credit-worthiness of the issuer. The traditional GICs are classified within Level 3
11-K
u8av6i31axqm2 7zd4gs
26 Jun 13
Annual report of employee stock purchases
12:00am
11-K
goql2n8u25ruc
25 Jun 14
Annual report of employee stock purchases
12:00am
6-K
EX-99.2
7cftyv
12 Jun 20
Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseases
1:10pm
11-K
uf0suiu9crsv895z
28 Jun 19
Annual report of employee stock purchases
2:51pm
11-K
dvn8f9
28 Jun 12
Annual report of employee stock purchases
12:00am
11-K
jojq2042nj08mth iq
26 Jun 13
Annual report of employee stock purchases
12:00am
11-K
fbfyczn0ji
28 Jun 12
Annual report of employee stock purchases
12:00am
6-K
EX-99.2
bhypg
28 Sep 09
Current report (foreign)
12:00am
11-K
3woo vx21vv2evabp0
26 Jun 20
Annual report of employee stock purchases
10:35am
6-K
EX-99.1
0izcqesqr8tf1g08
29 Jul 11
Free Translation of the French Language Original
12:00am
11-K
gpe37z
29 Jun 17
Annual report of employee stock purchases
12:00am
11-K
lf1kf79ypkj6
29 Jun 22
Annual report of employee stock purchases
11:46am
11-K
9dkwl kef9dux1zu
28 Jun 16
Annual report of employee stock purchases
12:00am
6-K
EX-99.2
wkxnnere2j
28 Apr 11
Sanofi-aventis and Regeneron Report
12:00am
11-K
ymkvuob1
28 Jun 16
Annual report of employee stock purchases
12:00am